Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience
Hyperleukocytosis in pediatric acute leukemia is associated with increased morbidity and mortality and at present there is no consensus on the use of leukapheresis (LPH) for its management. Our aim was to review characteristics and outcomes of newly diagnosed leukemia patients with hyperleukocytosis...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024808/ https://www.ncbi.nlm.nih.gov/pubmed/35455547 http://dx.doi.org/10.3390/children9040503 |
_version_ | 1784690698829692928 |
---|---|
author | Jones, Sandra Renee Rahrig, April Saraf, Amanda J. |
author_facet | Jones, Sandra Renee Rahrig, April Saraf, Amanda J. |
author_sort | Jones, Sandra Renee |
collection | PubMed |
description | Hyperleukocytosis in pediatric acute leukemia is associated with increased morbidity and mortality and at present there is no consensus on the use of leukapheresis (LPH) for its management. Our aim was to review characteristics and outcomes of newly diagnosed leukemia patients with hyperleukocytosis (HL) comparing those who received LPH and those who did not. An IRB approved retrospective case control study reviewed data from a single institution over a 10 year period. At our institution, LPH was used in 8 of 62 (13%) patients with hyperleukocytosis with minimal complications. Mean leukocyte count in patients who received LPH versus those who did not was 498 k cells/mm(3) and 237 k cells/mm(3), respectively. Patients who had symptoms of neurologic (63 vs. 17%) or pulmonary leukostasis (75 vs. 17%) were more likely to have undergone leukapheresis. The time from presentation to the initiation of chemotherapy was not different between those who received LPH and those who did not (mean of 35 h vs. 34 h). There was one death in the LPH group, that was the result of neurologic sequelae of hyperleukocytosis and not LPH itself. The use of LPH in patients with hyperleukocytosis is safe, well tolerated and does not alter time to chemotherapy at our institution. |
format | Online Article Text |
id | pubmed-9024808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90248082022-04-23 Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience Jones, Sandra Renee Rahrig, April Saraf, Amanda J. Children (Basel) Article Hyperleukocytosis in pediatric acute leukemia is associated with increased morbidity and mortality and at present there is no consensus on the use of leukapheresis (LPH) for its management. Our aim was to review characteristics and outcomes of newly diagnosed leukemia patients with hyperleukocytosis (HL) comparing those who received LPH and those who did not. An IRB approved retrospective case control study reviewed data from a single institution over a 10 year period. At our institution, LPH was used in 8 of 62 (13%) patients with hyperleukocytosis with minimal complications. Mean leukocyte count in patients who received LPH versus those who did not was 498 k cells/mm(3) and 237 k cells/mm(3), respectively. Patients who had symptoms of neurologic (63 vs. 17%) or pulmonary leukostasis (75 vs. 17%) were more likely to have undergone leukapheresis. The time from presentation to the initiation of chemotherapy was not different between those who received LPH and those who did not (mean of 35 h vs. 34 h). There was one death in the LPH group, that was the result of neurologic sequelae of hyperleukocytosis and not LPH itself. The use of LPH in patients with hyperleukocytosis is safe, well tolerated and does not alter time to chemotherapy at our institution. MDPI 2022-04-02 /pmc/articles/PMC9024808/ /pubmed/35455547 http://dx.doi.org/10.3390/children9040503 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jones, Sandra Renee Rahrig, April Saraf, Amanda J. Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience |
title | Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience |
title_full | Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience |
title_fullStr | Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience |
title_full_unstemmed | Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience |
title_short | Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience |
title_sort | leukapheresis in pediatric acute leukemia with hyperleukocytosis: a single-center experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024808/ https://www.ncbi.nlm.nih.gov/pubmed/35455547 http://dx.doi.org/10.3390/children9040503 |
work_keys_str_mv | AT jonessandrarenee leukapheresisinpediatricacuteleukemiawithhyperleukocytosisasinglecenterexperience AT rahrigapril leukapheresisinpediatricacuteleukemiawithhyperleukocytosisasinglecenterexperience AT sarafamandaj leukapheresisinpediatricacuteleukemiawithhyperleukocytosisasinglecenterexperience |